• Gene fusion; HGNC; 7135; AFF1 + HGNC; 7132; KMT2A; Name(s)=KMT2A-AFF1, MLL-AFF1, ALL-1/AF4 (from parent cell line).
  
• Mutation; HGNC; 3765; FLT3; Unexplicit; Internal tandem duplication (FLT3-ITD); ClinVar=VCV000016270; Zygosity=Unspecified (from parent cell line).
  
• Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Heterozygous (PubMed=29491412; PubMed=29454094).
  

PubMed=29491412; DOI=10.1038/s41388-018-0150-2; PMCID=PMC5955861
Gerlach D., Tontsch-Grunt U., Baum A., Popow J., Scharn D., Hofmann M.H., Engelhardt H., Kaya O., Beck J., Schweifer N., Gerstberger T., Zuber J., Savarese F., Kraut N.
The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML.
Oncogene 37:2687-2701(2018)

PubMed=29454094; DOI=10.1016/j.canlet.2018.02.018
Tontsch-Grunt U., Rudolph D., Waizenegger I.C., Baum A., Gerlach D., Engelhardt H., Wurm M., Savarese F., Schweifer N., Kraut N.
Synergistic activity of BET inhibitor BI 894999 with PLK inhibitor volasertib in AML in vitro and in vivo.
Cancer Lett. 421:112-120(2018)